AstraZeneca Pharmaceuticals LP
NEWS
Biopharma companies from across the globe share business and development updates.
AstraZeneca and Merck plan on seeking regulatory approval for Lynparza as a treatment for a subset of prostate cancer patients based on the Phase III PROfound data.
The U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) to AstraZeneca over its supplemental New Drug Application (sNDA) for Farxiga (dapagliflozin) as an adjunct treatment to insulin for type 1 diabetes (T1D) when insulin alone doesn’t keep blood sugar levels under control.
Exiting the last week of June and heading into July, a number of companies announced results from ongoing clinical trials. Here’s a look.
AstraZeneca recently reported positive interim data from clinical trials of two, and potentially a third, of its drugs for cancer.
Here’s a look at some of last week’s clinical trial announcements, including some from the American Society of Clinical Oncology Annual Meeting you might have missed.
During an interim analysis of ELEVATE-TN data, AstraZeneca said Calquence met primary endpoints in patients with previously untreated CLL.
ASCO called rare cancer treatments the “advance of the year” in oncology.
AstraZeneca underwent a restructuring earlier this year with an increased focus on oncology.
JOBS
IN THE PRESS